FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Go back to FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.| Abbott Laboratories (NYSE: ABT) | Delayed: 102.61 +0.38 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $102.23 | 52 Week High | $46.38 | |||
| Open | $101.83 | 52 Week Low | $36.00 | |||
| Day High | $103.19 | P/E | 68.41 | |||
| Day Low | $101.50 | EPS | $1.50 | |||
| Volume | 27,075,235 | |||||
| (NASDAQ: FRNM) | Delayed: 17.11 +0.82 (5.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.29 | 52 Week High | $ | |||
| Open | $16.35 | 52 Week Low | $ | |||
| Day High | $17.26 | P/E | N/A | |||
| Day Low | $16.27 | EPS | $ | |||
| Volume | 6,047,306 | |||||
